Transcranial Photobiomodulation (tPBM) Treatment for Autism Spectrum Disorder

Led By T. Atilla Ceranoglu, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants with at least moderately severity of ASD symptoms as demonstrated by SRS raw score ≥ 85 and CGI-ASD severity score ≥ 4
Be between 18 and 65 years old
Must not have
Be younger than 18 years old
Be older than 65 years old
Screening 3 weeks
Treatment Varies
Follow Upthrough study completion, an average of 8 weeks
Awards & highlights

Study Summary

This trial will test a new treatment for ASD and measure its safety, tolerability, and effectiveness.

Eligible Conditions
  • Autism Spectrum Disorder
  • Autism

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have a significant level of autism symptoms, as shown by certain test scores.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
ASD symptoms as measured by change through study completion on the Social Responsiveness Scale-2nd Edition (SRS-2)
ASD symptoms as measured by change through study completion, on the Clinical Global Impression of Improvement of Autism Spectrum Disorder (CGI-ASD-I)
Secondary outcome measures
Therapeutic procedure
Treatment-related changes in associated executive functions
Treatment-related changes in associated psychopathology
+5 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Transcranial Photobiomodulation (tPBM) TreatmentActive Control1 Intervention
Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light is applied to forebrain.
Group II: Placebo/ Sham TreatmentPlacebo Group1 Intervention
The sham treatment will mimic the tPBM procedure, while delivering no light.

Find a site

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,833 Previous Clinical Trials
13,567,277 Total Patients Enrolled
42 Trials studying Autism Spectrum Disorder
3,102 Patients Enrolled for Autism Spectrum Disorder
T. Atilla Ceranoglu, MDPrincipal Investigator
Massachusetts General Hospital
1 Previous Clinical Trials
60 Total Patients Enrolled

Media Library

Placebo/ Sham Clinical Trial Eligibility Overview. Trial Name: NCT05363982 — N/A
Autism Spectrum Disorder Research Study Groups: Placebo/ Sham Treatment, Transcranial Photobiomodulation (tPBM) Treatment
Autism Spectrum Disorder Clinical Trial 2023: Placebo/ Sham Highlights & Side Effects. Trial Name: NCT05363982 — N/A
Placebo/ Sham 2023 Treatment Timeline for Medical Study. Trial Name: NCT05363982 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there openings for individuals to participate in the trial?

" informs us that this medical trial is currently seeking participants; the original posting date was February 11th, 2022 and it has been recently amended on May 2nd, 2022."

Answered by AI

How extensive is the participant pool for this medical experiment?

"Affirmative. According to, this research project is on the hunt for 54 volunteers from one medical centre and was initially posted on February 11th 2022 with recent edits dated May 2nd 2022."

Answered by AI

What is the ultimate goal of this research endeavor?

"The primary aim of this trial, which is set to last an average of 8 weeks, will evaluate the change in ASD symptoms based on scores from the Social Responsiveness Scale-2nd Edition (SRS-2). Assessments related to treatment's effect on associated psychopathology such as Attention Deficit Hyperactivity Disorder (ADHD) and social cognition functions will be conducted with the Clinical Global Impression of Improvement in ADHD scale (CGI-ADHD-I), Massachusetts General Hospital Social Emotional Competence Scale (MGH-SEC Scale), and Behavior Rating Inventory of Executive Function - Adult Self Report Version (BRIEF-"

Answered by AI

Does your research encompass elderly individuals aged 85 years and above?

"Eligible individuals for this trial must be between 18 and 59 years old."

Answered by AI

Could I become a participant in this medical experiment?

"With the goal of recruiting 54 participants, this trial is seeking individuals between 18 and 59 years old with autism spectrum disorder. Interested applicants must meet certain requirements such as: being able to comprehend the study's purpose; possessing a valid decision-making capacity; having an SRS raw score no less than 85 combined with CGI-ASD severity score equal or above 4; conforming to Diagnostic and Statistical Manual-5th edition diagnostic criteria for Autism Spectrum Disorder (DSM 5) established by clinical diagnostic interview; displaying sufficient communication capabilities in order to collaborate effectively with investigators/study coordinators involved in the project. Furthermore, if female potential"

Answered by AI

Who else is applying?

What site did they apply to?
Massachusetts General Hospital
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
Recent research and studies
~9 spots leftby Feb 2024